BioArctic publishes the Annual Report and Sustainability Report for 2025

Rhea-AI Summary

BioArctic (Nasdaq: B) published its Annual Report 2025, with the Sustainability Report and Corporate Governance Report integrated into the document. The company highlights a breakthrough Alzheimer’s drug now on the global market, several licence agreements, a broad pipeline and record-high profits in 2025.

The report aligns sustainability reporting with the European CSRD and ESRS frameworks and is available for download from the company's investor website.

Positive

• Breakthrough Alzheimer’s drug launched on the global market
• Record-high profits reported for 2025
• Several licence agreements executed during 2025
• Integrated Sustainability Report aligned with CSRD/ESRS

Negative

• None.

News Market Reaction – B

-5.84%

-5.84% Session close to close

In the Apr 21 session, B declined 5.84%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, April 21, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Annual Report for 2025 has been published and is available on the company's website. The company's Sustainability Report and Corporate Governance Report are integrated with the Annual Report.

"In 2025 BioArctic entered a new phase. Behind us, we left an era that, for just over 20 years, shaped the company we are today. 2025 was a fantastic year for BioArctic, with a breakthrough drug against Alzheimer's disease on the global market, a broad and growing pipeline, several license agreements and a financial year that resulted in record-high profits. It is with pride that I look back on our first year in BioArctic's new era of growth," says Gunilla Osswald, CEO of BioArctic.

BioArctic's work for a sustainable future is encapsulated in the concepts of Sustainable innovation and Sustainable business. The Sustainability Report summarizes and structures the company's sustainability efforts and is part of the company's objective to increase transparency and fulfil stakeholders' requirements. To meet these expectations, the content and structure of the report is inspired by the European Corporate Sustainability Reporting Directive (CSRD) and the European Sustainability Reporting Standards (ESRS).

The Annual Report, which is attached, can also be downloaded from the company's website, www.bioarctic.com (Investors/Financial reports and presentations).

This disclosure contains information that BioArctic is obliged to make public pursuant to the Swedish Securities Markets Act. The information was released for public disclosure, through the agency of the contact person below, on April 21, 2026, at 20:00 CET.  

For further information, please contact:

Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180

Anders Martin-Löf, CFO 
E-mail: anders.martin-lof@bioarctic.com
Telephone: +46 70 683 79 77 

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/bioarctic-publishes-the-annual-report-and-sustainability-report-for-2025,c4337913

The following files are available for download:

https://mb.cision.com/Main/9978/4337913/4049798.pdf	BioArctic Annual and Sustainability Report 2025
https://mb.cision.com/Main/9978/4337913/4050491.zip	bioa-2025-12-31-0-sv.zip
https://mb.cision.com/Public/9978/4337913/823dd66facc6232c.pdf	Press release (PDF)

View original content:https://www.prnewswire.com/news-releases/bioarctic-publishes-the-annual-report-and-sustainability-report-for-2025-302749236.html

SOURCE BioArctic

FAQ

When was BioArctic (B) Annual Report 2025 published?

The Annual Report 2025 was published on April 21, 2026. According to the company, the report and integrated Sustainability and Corporate Governance reports were released publicly on that date for investors.

What does BioArctic say about its Alzheimer’s drug in the Annual Report (B)?

BioArctic states the company has a breakthrough Alzheimer’s drug on the global market. According to the company, this marks a new phase with commercialization alongside a growing pipeline and licence activity.

How did record-high profits in 2025 affect BioArctic (B)?

The company reports record-high profits in 2025, signaling stronger financial performance. According to the company, this financial year supported its new growth era and accompanied multiple licence agreements and pipeline expansion.

Where can investors download BioArctic's Annual Report 2025 (B)?

Investors can download the Annual Report 2025 from BioArctic's website under Investors/Financial reports and presentations. According to the company, the full report and integrated sustainability sections are available for download.

How is BioArctic's Sustainability Report aligned with EU rules (B)?

The Sustainability Report is structured using principles inspired by the CSRD and ESRS. According to the company, this alignment increases transparency and aims to meet stakeholder reporting expectations.